A RANDOMIZED, CONTROLLED PHASE III TRIAL OF SORAFENIB WITH OR WITHOUT CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (STAH)

被引：2
|
作者：
Park, J. -W. [1 ]
Kim, Y. J. [2 ]
Kim, D. Y. [3 ]
Bae, S. H. [4 ]
Yeon, J. E. [5 ]
Han, S. Y. [6 ]
Hwang, J. S. [7 ]
Lee, Y. -J. [8 ]
Cheong, J. Y. [9 ]
Kwon, O. S. [10 ]
Kim, H. Y. [11 ]
Lee, H. C. [12 ]
Heo, J. [13 ]
Kim, B. H. [1 ]
Paik, S. W. [14 ]
机构：
[1] Natl Canc Ctr, Goyang, South Korea
[2] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[3] Severance Hosp, Seoul, South Korea
[4] Catholic Univ Hosp Korea, Seoul, South Korea
[5] Korea Univ, Guro Hosp, Seoul, South Korea
[6] Dong A Univ, Med Ctr, Busan, South Korea
[7] Keimyung Univ, Dongsan Med Ctr, Daegu, South Korea
[8] Busan Paik Hosp, Busan, South Korea
[9] Ajou Univ Hosp, Suwon, South Korea
[10] Gachon Univ, Gil Hosp, Inchon, South Korea
[11] Boramae Med Ctr, Seoul, South Korea
[12] Asan Med Ctr, Seoul, South Korea
[13] Busan Natl Univ Hosp, Busan, South Korea
[14] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)31514-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1335
引用
收藏
页码：S857 / S857
页数：1
相关论文
共 50 条
  • [31] Comparison of CalliSpheres(R) microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial
    Shi, Zhongxing
    Wang, Dongqing
    Kang, Tanrong
    Yi, Ru
    Cui, Liming
    Jiang, Huijie
    RADIOLOGY AND ONCOLOGY, 2023, 57 (01) : 70 - 79
  • [32] Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial
    Peng, Zhenwei
    Fan, Wenzhe
    Zhu, Bowen
    Li, Jiaping
    Kuang, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [33] Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease
    Kirstein, Martha M.
    Voigtlaender, Torsten
    Schweitzer, Nora
    Hinrichs, Jan B.
    Marquardt, Jens
    Woerns, Marcus-Alexander
    Kloeckner, Roman
    Fruendt, Thorben W.
    Ittrich, Harald
    Wacker, Frank
    Rodt, Thomas
    Manns, Michael P.
    Wege, Henning
    Weinmann, Arndt
    Vogel, Arndt
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (02) : 238 - 246
  • [34] Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarteria Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Ikeda, Masafumi
    Torimura, Takuji
    Tanabe, Nobukazu
    Aikata, Hiroshi
    Izumi, Namiki
    Yamasaki, Takahiro
    Nojiri, Shunsuke
    Hino, Keisuke
    Tsumura, Hidetaka
    Kuzuya, Teiji
    Isoda, Norio
    Moriguchi, Michihisa
    Aino, Hajime
    Ido, Akio
    Kawabe, Naoto
    Nakao, Kazuhiko
    Wada, Yoshiyuki
    Ogasawara, Sadahisa
    Yoshimura, Kenichi
    Okusaka, Takuji
    Furuse, Junji
    Kokudo, Norihiro
    Okita, Kiwamu
    Johnson, Philip James
    Arai, Yasuaki
    LIVER CANCER, 2022, 11 (04) : 354 - 367
  • [35] Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
    Bruix, Jordi
    Raoul, Jean-Luc
    Sherman, Morris
    Mazzaferro, Vincenzo
    Bolondi, Luigi
    Craxi, Antonio
    Galle, Peter R.
    Santoro, Armando
    Beaugrand, Michel
    Sangiovanni, Angelo
    Porta, Camillo
    Gerken, Guido
    Marrero, Jorge A.
    Nadel, Andrea
    Shan, Michael
    Moscovici, Marius
    Voliotis, Dimitris
    Llovet, Josep M.
    JOURNAL OF HEPATOLOGY, 2012, 57 (04) : 821 - 829
  • [36] Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Cainap, Calin
    Qin, Shukui
    Huang, Wen-Tsung
    Chung, Ik-Joo
    Pan, Hongming
    Cheng, Ying
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chen, Pei-Jer
    Toh, Han Chong
    Gorbunova, Vera
    Eskens, Ferry
    Qian, Jiang
    McKee, Mark D.
    Ricker, Justin L.
    Carlson, Dawn M.
    El Nowiem, Saied
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [37] A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
    Rimassa, Lorenza
    Pressiani, Tiziana
    Boni, Corrado
    Carnaghi, Carlo
    Caremoli, Elena Rota
    Fagiuoli, Stefano
    Foa, Paolo
    Salvagni, Stefania
    Cortesi, Enrico
    Tronconi, Maria Chiara
    Personeni, Nicola
    Bozzarelli, Silvia
    Banzi, Maria Chiara
    Fanello, Silvia
    Lutman, Fabio Romano
    Giordano, Laura
    Santoro, Armando
    ONCOLOGIST, 2013, 18 (04): : 379 - 380
  • [38] Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis
    Zhang, Yingqiang
    Fan, Wenzhe
    Wang, Yu
    Lu, Ligong
    Fu, Sirui
    Yang, Jianyong
    Huang, Yonghui
    Yao, Bwang
    Li, Jiaping
    ONCOLOGIST, 2015, 20 (12): : 1417 - 1424
  • [39] Transradial versus transfemoral access without closure device for transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized trial
    Zhang, Xiaowu
    Luo, Yingen
    Tsauo, Jiaywei
    Zhao, He
    Gong, Tao
    Li, Jingui
    Li, Yawei
    Zeng, Huiying
    Sun, Wei
    Li, Xiao
    EUROPEAN RADIOLOGY, 2022, 32 (10) : 6812 - 6819
  • [40] Transradial versus transfemoral access without closure device for transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized trial
    Xiaowu Zhang
    Yingen Luo
    Jiaywei Tsauo
    He Zhao
    Tao Gong
    Jingui Li
    Yawei Li
    Huiying Zeng
    Wei Sun
    Xiao Li
    European Radiology, 2022, 32 : 6812 - 6819
12345